BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 16617300)

  • 1. Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes.
    Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
    Gene Ther; 2006 Aug; 13(16):1235-43. PubMed ID: 16617300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy.
    Liu Y; Deisseroth A
    Cancer Gene Ther; 2006 Sep; 13(9):845-55. PubMed ID: 16710344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H; Zhang L; Tang Y; Deisseroth A
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy.
    Lee YJ; Galoforo SS; Battle P; Lee H; Corry PM; Jessup JM
    Cancer Gene Ther; 2001 Jun; 8(6):397-404. PubMed ID: 11498759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice.
    Cao X; Ju DW; Tao Q; Wang J; Wan T; Wang BM; Zhang W; Hamada H
    Gene Ther; 1998 Aug; 5(8):1130-6. PubMed ID: 10326037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
    Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A
    Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma cultures show different susceptibility towards E1A-, E1B-19 kDa- and fiber-modified replication-competent adenoviruses.
    Schmitz M; Graf C; Gut T; Sirena D; Peter I; Dummer R; Greber UF; Hemmi S
    Gene Ther; 2006 Jun; 13(11):893-905. PubMed ID: 16482201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
    Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q
    Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel attenuated replication-competent adenovirus for melanoma therapy.
    Peter I; Graf C; Dummer R; Schaffner W; Greber UF; Hemmi S
    Gene Ther; 2003 Apr; 10(7):530-9. PubMed ID: 12646858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
    Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
    Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma.
    Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
    Hum Gene Ther; 2004 Jul; 15(7):637-47. PubMed ID: 15242524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition.
    Yoo JY; Kim JH; Kim J; Huang JH; Zhang SN; Kang YA; Kim H; Yun CO
    Gene Ther; 2008 May; 15(9):635-51. PubMed ID: 18273054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy.
    Liu Y; Ye T; Maynard J; Akbulut H; Deisseroth A
    Cancer Gene Ther; 2006 Apr; 13(4):346-56. PubMed ID: 16179927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma.
    Topf N; Worgall S; Hackett NR; Crystal RG
    Gene Ther; 1998 Apr; 5(4):507-13. PubMed ID: 9614575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene.
    Porosnicu M; Mian A; Barber GN
    Cancer Res; 2003 Dec; 63(23):8366-76. PubMed ID: 14678998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
    Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
    J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
    Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
    Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.